Clinical Endocrinology

Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies

Authors

  • Silvia A. Eskes,

    Corresponding author
    1. Department of Endocrinology and Metabolism Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • Correspondence: Silvia A. Eskes, Department of Endocrinology and Metabolism, Academic Medical Center, room F5-168, Meibergdreef 9, Amsterdam 1105AZ, The Netherlands. Tel.: +31 20 5666071; Fax: +31 20 6917682; E-mail s.eskes@sfg.nl

    Search for more papers by this author
  • Erik Endert,

    1. Department of Endocrinology and Metabolism Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Search for more papers by this author
  • Eric Fliers,

    1. Department of Endocrinology and Metabolism Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Search for more papers by this author
  • Erwin Birnie,

    1. Department of Statistics and Education, St. Franciscus Gasthuis Rotterdam, Rotterdam, The Netherlands
    2. Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands
    Search for more papers by this author
  • Birgit Hollenbach,

    1. Institute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for more papers by this author
  • Lutz Schomburg,

    1. Institute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for more papers by this author
  • Josef Köhrle,

    1. Institute for Experimental Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for more papers by this author
  • Wilmar M. Wiersinga

    1. Department of Endocrinology and Metabolism Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Search for more papers by this author

Summary

Context

Euthyroid thyroid peroxidase (TPO-Ab)-positive subjects are at risk for progression to subclinical and overt autoimmune hypothyroidism. Previous studies have shown a decrease in TPO-Ab and improvement of quality-of-life (QoL) in L-T4-treated hypothyroid patients upon selenium supplementation.

Objectives

To evaluate in euthyroid TPO-Ab-positive women without thyroid medication whether selenite decreases TPO-Ab and improves QoL.

Design

Randomized, placebo-controlled, double-blind study.

Patients and methods

Euthyroid (TSH 0·5–5·0 mU/l, FT4 10–23 pm) women with TPO-Ab ≥ 100 kU/l were randomized to receive 200 mcg sodium selenite daily (= 30) or placebo (= 31) for 6 months. TSH, FT4, TPO-Ab, selenium (Se), selenoprotein P (SePP) and QoL were measured at baseline, 3, 6 and 9 months.

Results

There were no differences in baseline characteristics between the Se group and the placebo group. During selenite supplementation, serum Se and SePP did not change in the placebo group, but increased in the Se group. TPO-Ab and TSH did not change significantly in any group. TPO-Ab in the Se group were 895 (130–6800) at baseline, 1360 (60–7050) kU/l at 6 months, in the placebo group 1090 (120–9200) and 1130 (80–9900) kU/l, respectively (median values with range). TSH in the Se group was 2·1 (0·5–4·3) at baseline, 1·7 (0·0–5·3) mU/l at 6 months, in the placebo group 2·4 (0·7–4·4) and 2·5 (0·2–4·3) mU/l, respectively. QoL was not different between the groups.

Conclusion

Six months selenite supplementation increased markers of selenium status but had no effect on serum TPO-Ab, TSH or quality-of-life in euthyroid TPO-Ab-positive women.

Ancillary